Zhongling Feng

Zhongling Feng has extensive work experience in the biotech and pharmaceutical industry. Zhongling is currently serving as the VP Clinical Development at IO Biotech since January 2024. Prior to this role, they worked at AbbVie as the Executive Medical Director-Global Development Lead from March 2022 to December 2023. Zhongling also held positions at Takeda as a Senior Medical Director/Global Clinical Lead from September 2019 to April 2022, and as a Medical Director from January 2019 to September 2019. Additionally, Zhongling Feng worked as a Medical Director at Acerta Pharma B.V. (A member of the AstraZeneca Group) from October 2017 to January 2019, and as the Director of Clinical Development at ACEA Biosciences from October 2014 to September 2017. Zhongling also held roles at Western Biologics LLC as the CSO from May 2014 to December 2014, and as the Sr. Director of Research & Development from March 2014 to December 2014. Furthermore, they worked as a Medical Director at Targazyme from September 2012 to October 2014, and as a Consulting CSO at Viropro Inc from August 2013 to March 2014. Prior to that, they worked as a Scientist at GNF from September 2012 to September 2013, and as the Director of Product Development at Animal Cell Therapies, Inc. from April 2012 to July 2012.

Zhongling Feng completed an Executive Education program in Leadership and Management at The Wharton School in 2020-2021. In 2013-2014, Feng obtained a Professional Certificate in Clinical Trials Design and Management from UC San Diego. Additionally, Feng was a Postdoctoral Research Fellow at Harvard Medical School in 2001-2002. Feng holds an M.D. and Ph.D. in Clinical Medicine and Oncology from China Medical University. Feng also obtained various certifications in leadership, management, and strategic management from Wharton Online.